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ABSTRACT
Introduction Patients with negative blood cultures (BCx) 
represent 85%–90% of all patients with BCx taken during 
hospital admission. This population usually includes a 
heterogeneous group of patients admitted with infectious 
diseases or febrile syndromes that require a blood culture. 
There is very little evidence of the clinical characteristics 
and antibiotic treatment given to these patients.
Methods and analysis In a preliminary exploratory 
prospective cohort study of patients with BCx taken, 
the clinical/therapeutic characteristics and outcomes/
antimicrobial stewardship opportunities of a population of 
patients with negative BCx will be analysed. In the second 
phase, using a cluster randomised crossover design, 
the implementation of an antimicrobial stewardship 
intervention targeting patients with negative BCx will be 
evaluated in terms of quality of antimicrobial use (duration 
and de- escalation), length of hospital stay and mortality.
Ethics and dissemination This study has been and 
registered with  clinicaltrials. gov. The findings of our study 
may support the implementation in clinical practice of an 
antimicrobial stewardship intervention to optimise the use 
of antibiotics in patients with negative BCx. The results of 
this study will be published in peer- reviewed journals and 
disseminated at national and international conferences.
Trial registration number NCT03535324.
InTRoduCTIon
Performing blood cultures (BCx) is usual 
practice in patients admitted to the emer-
gency services with signs of severe infection 
and those admitted to hospital as inpatients; 
it is also recommended practice for most 
admitted patients with suspected infec-
tious syndromes. There is evidence that 
the management of bacteraemia by infec-
tious diseases specialists is associated with a 
better prognosis,1 but very little about the 
management of patients who continue to 
show signs of infection despite a negative 
blood culture result. The treatment and 
management of patients with negative BCx 
is not very common, and in the literature 
is confined to specific syndromes such as 
endocarditis.2 In general, only 10%–15% of 
BCx are positive.3
At the same time, the population with 
negative BCx is very heterogeneous and 
there is at present very little information 
available about the epidemiological, clin-
ical, therapeutic and prognostic character-
istics of this population. In some infectious 
syndromes, such as pneumonia or pyelo-
nephritis, the absence of bacteraemia has 
been associated with a better prognosis.4 5 In 
addition, prognostic tests for these patients 
have not been systematically established in 
Strengths and limitations of this study
 ► A cluster crossover design was selected to control 
for potential confounding factors and to ensure its 
feasibility given that this is an educational interven-
tion in which potential contamination through pre-
scriber exposure can be controlled.
 ► Since the nature of the intervention groups does not 
allow for blinding, a robust primary outcome was se-
lected (days of treatment) and external assessment 
by a blinded committee was included.
 ► This is a multicentre study.
 ► The findings could make a significant contribution to 
improving antimicrobial prescribing in patients with 
negative blood cultures.
 ► Limitations of the study include: the risk of selection 
bias in cluster randomised trials; the nature of the 
Antimicrobial Stewardship Programs (ASP) interven-
tion may consist basically of an unsolicited advice 
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Table 1 Schedule of enrolment and assessments: cohort study and cluster- randomised trial—NO- BACT, 2018–2020
Timepoint









Enrolment   X       
Assessment of adequacy of antimicrobial treatment   X X   
Evaluation of mortality and length of stay       X
 
 Timepoint
 Cluster- randomised trial (October 2019–December 2020)
Visit 0 (2 days 
post- BCx)
Visit 1 (3 days 
post- BCx)
Visit 2 (4 days 
post- BCx)
Visit 3 (5–7 
days post- 
BCx)
Visit 4 or end 
of antibiotic 
treatment
Visit 5 (30 days 
post- BCx)
Clinical evaluation* X X X X X X
Assessment of 
prescription adequacy†
X           
Blood analysis‡ X   X       
De- escalation or 
indication for stopping 
antibiotics
  X         
Acceptance record of 
the intervention
  X   X     
Assessment of de- 
escalation and oral 
sequential therapy
    X X     
*Vital signs/symptoms, capillary blood glucose (if available), diuresis (if available), collections drainage (if available), anamnesis and physical 
examination ‘exploration of devices’, description of focus and severity (quick Sequential Organ Failure Assessment score, description of 
severity of Systemic Inflammatory Response Syndrome).
†Peer evaluation of adherence to the reference guide, based on clinical syndrome and severity.
‡Hemogram, general biochemistry with procalcitonin and C- reactive protein, gasometry with lactate.
BCx, blood cultures.
the available literature. The treatment strategies and 
evaluation of antibiotics in this population are often 
conflicting. Some studies that have compared the char-
acteristics of patients with bacteraemia and those with 
negative BCx in specific infectious syndromes have 
observed a trend towards greater use of antibiotics in 
the negative BCx group.4 Most patients with negative 
BCx receive antibiotic treatment, which is maintained 
regardless of the result. In short, there is a lack of infor-
mation about the indications for and adequacy of the 
use of antimicrobials in these patients.
Antimicrobial Stewardship Programs (ASP) are devel-
oped in clinical circumstances where an intervention 
in the treatment of patients is associated with improved 
patient prognosis and cost- effective management of the 
available resources. The conditions of the intervention 
may be established randomly or based on predefined 
selection criteria: a specific population, a specific antibi-
otic, a specific infectious syndrome or specific characteris-
tics of the prescription (duration, sequential oral therapy, 
etc).6 Since this is a simple population to identify, possible 
areas of interest include knowledge of the incorrect use 
of antimicrobials in patients with negative BCx and the 
potential beneficial impact of the ASP on these patients. 
With respect to the type of intervention recommended 
for development of an ASP, audits and feedback have 
proven to be the most effective for modifying prescribing 
habits.7 8 Audit- based programmes are associated with 
improvements in the quality of antimicrobial use and 
improved resource management, without negatively 
affecting patient safety. The objective of an audit is to eval-
uate and, where appropriate, modify different elements 
of the prescription. In the present study, an intervention 
is proposed on day 3 and days 5–7 after BCx extraction to 
evaluate the possibilities of de- escalation, sequential oral 
therapy or end of early treatment, based on the available 
evidence.
A systematic review and meta- analysis conducted by 
Davey et al8 highlighted that the lack of consistency 
between the multiple ASP interventions included meant 
that the quality of the evidence was inadequate. Most 
studies published to date included in that review used a 
quasi- experimental design, a before–after intervention 
and frequently lacked a non- intervention control arm. 
Controlled clinical trials with cluster- type assignment 
on the other hand are presented as a suitable design 
for assessing the impact of interventions on patient 
groups.9 Interventions with an educational compo-
nent aimed at the group of prescribers are subject to 
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Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Cohort study
Age ≥18 years with BCx 
extraction (two samples 
taken from peripheral veins).
Patients discharged from 
hospital within the first 48 hours 
following the BCx extraction.
  Patients with life expectancy of 
less than 30 days.
Cluster- randomised trial*
  Age ≥18 years being 
treated in the specific 
preselected departments 
and have had BCx that 
meet the following criteria:
1.  Negative BCx.
2.  Receiving active 
antibiotic therapy within 
48 hours of extraction.
Patients discharged from 
hospital within the first 48 hours 
following the BCx extraction.
  Limitation of therapeutic effort 
indication.
  Patients with life expectancy of 
less than 30 days.
  Severe neutropenia at the time 
of randomisation (<500 cells/
mm3).
  Pregnancy or lactation.
  A positive BCx in the previous 
7 days.
*Cluster: units assigned to intervention, clinical units 
treating patients with BCx extracted for diagnosis, in which 
optimisation of the educational intervention is deemed to be 
most beneficial, according to the results of the cohort study 
performed in phase I.
BCx, blood cultures.
Figure 1 Crossover design of the NO- BACT study.
functional area. Group clinical trials (clusters) make it 
possible to assign interventions to complete functional 
groups such as clinical units, specific wards or hospitals.
There are no controlled intervention studies in the 
recent literature on the optimisation of patients with 
negative BCx. Hence, the two main research objectives of 
the NO- BACT study are:
1. To investigate the clinical characteristics and thera-
peutic management of a cohort of patients with BCx 
extractions (negative and positive). In this exploratory 
phase, preliminary information will be gathered for a 
predefined intervention aimed at the optimisation of 
antibiotic treatment.
2. To investigate the efficacy and safety of a programme 
to optimise antibiotic use aimed at patients with neg-




This study has two separate phases, each with a different 
design.
Phase I is an exploratory prospective cohort study of 
patients who have had a BCx extraction; phase II is a two- 
group, CRT with randomised sequential crossover assign-
ment to an ASP intervention.
Participants and study settings
This multicentre study will be conducted at three 
academic hospitals in Spain with extensive experience of 
ASPs: Hospital Universitario Virgen Macarena (Seville), 
Hospital Universitario Puerta del Mar (Cádiz) and 
Hospital Universitario Lozano- Blesa (Zaragoza). For the 
CRT, each hospital will participate with six clusters corre-
sponding to six clinical units (functional clinical depart-
ments such as Intensive Care Unit (ICU), Urology, etc), 
which will be selected in accordance with the conclusions 
of the preliminary cohort study, selecting those offering 
the best optimisation opportunities for ASP intervention. 
The study period is estimated to last 3 years (2018–2020): 
9 months for start- up activities, 1 year for the cohort study 
(6 months of patient recruitment, 6 months for anal-
ysis) and 15 months for the CRT (9 months of recruit-
ment, 6 months for analysis and dissemination of results) 
(table 1).
The second phase of this study will be a CRT involving 
a cluster- level public health intervention. The subjects of 
this educational intervention will be health professionals 
in participating clinical units. Inclusion and exclusion 
criteria are included in table 2.
The institutional review boards involved (online supple-
mentary file) and the Spanish Regulatory Agency have 
granted a waiver of informed consent for the study inter-
vention. The study involves no more than minimal risk to 
patients in the care of participating health professionals, 
and patients will be verbally informed of their participa-
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Figure 2 Experimental intervention—NO- BACT.
Recruitment process
Cohort study
Patients who have had BCx taken will be detected via 
entries made by the microbiology laboratory in the 
hospital clinical records. Clinical and treatment- related 
data will be obtained via a prospective review of clinical 
records and electronic prescription programmes.
Cluster-randomised trial
Patients will be identified by the microbiology laboratory. 
Each week a list will be generated of all negative BCx 
performed on patients in the participating cluster 2 days 
previously. Prescriptions for antibiotic treatment 2 days 
after extraction will be confirmed through the electronic 
prescription programme.
Randomisation and allocation concealment
Assignment to intervention will be made at the cluster 
level. Each hospital will participate with six clinical units 
(A, B, C, D, E, F), making 18 clusters in all. Selection of 
these units will be based on the conclusions of the cohort 
study, selecting those offering the best optimisation 
opportunities.
Randomisation will be based on a centralised, comput-
erised random number generator, specifically designed 
for the purpose. A copy of the randomisation list will be 
kept in a safe place in the event that technical problems 
arise. Allocation to the control or experimental interven-
tion will be announced just before implementation to 
avoid selection bias.
There will be six interventional periods of 6 weeks 
each. In the three first periods, the assignment to inter-
vention phase, each cluster will be randomly assigned 
to the control or experimental arm on day 1 (figure 1). 
Cross- reassignment will be made (crossover phase) in the 
fourth, fifth and sixth periods. Each cluster will have a 
‘washout’ period of 3 months between phases.
Interventions
The intervention will be made at the cluster level.
Experimental group
In clusters assigned to the experimental intervention, the 
antibiotic prescriptions of selected cases will be evaluated 
on day 3 of treatment. The evaluation will be by peer 
review of two physicians participating in the ASP to assess 
the suitability of the treatment prescribed based on local 
hospital guidelines (figure 2). On the basis of this evalu-
ation, recommendations will be made for: withdrawal of 
antibiotic treatment if it is considered that there are no 
indications for it; de- escalation, in light of clinically signif-
icant microbiology results in other biological samples, or 
empirical de- escalation, based on local guidelines and 
depending on the syndrome and baseline characteris-
tics of the patient; and/or evaluation of a switch to oral 
therapy if possible. Recommendations will be recorded 
on a specific form designed for the study. In patients 
who continue antibiotic treatment after the interven-
tion on day 3, a new physician peer review process will be 
implemented on day 5 to assess the possibility of a switch 
to oral therapy if this has not been done previously, or 
to plan for end of treatment, based on the recommen-
dations of the antibiotic reference guide. Based on the 
day 5 evaluation, an intervention will be performed on 
days 5–7 recommending a switch to oral treatment and/
or treatment finalisation, as indicated.
Control group
Antibiotic treatment of patients with negative BCx will 
be prescribed by the physician in charge as per clinical 
judgement.
Schedule of visits
The schedule of visits and assessments for the cohort study 
and cluster- randomised trial are described in table 1.
With respect to the CRT, patients included will be 
followed for 28 days after BCx extraction. Follow- up will 
be organised in five scheduled visits: visit 0 (2 days after 
BCx extraction), visit 1 (3 days after BCx extraction), visit 
2 (4 days after BCx extraction), visit 3 (between day 5 and 
day 7 after BCx extraction), visit 4, or end- of- treatment 
visit (if antibiotic treatment remains active after previous 
visits; if treatment finished at visits 1 or 3, those visits will 
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The primary outcome measure will be the percentage of 
patients with inadequate treatment at predefined eval-
uation timepoints (day 2 and days 5–7 following BCx 
extraction), depending on medical indication, coverage, 
route of administration and treatment duration.
Secondary outcomes include mortality at 30 days 
following BCx extraction and length of hospital stay.
Explanatory variables will be analysed (1) to inves-
tigate whether the prognosis of patients with negative 
BCx differs from those with positive BCx; (2) to identify 
prognostic factors in patients with negative BCx suscep-
tible to intervention and compare them with prognostic 
predictors in patients with positive BCx; (3) to compare 
the quality of antibiotic use in patients with negative and 
positive BCx.
Cluster-randomised trial
The CRT was designed to evaluate the efficacy and safety 
of a specific ASP to reduce the consumption of antibiotics 
(using days of treatment (DoT) as primary outcome) in 
patients with negative BCx. Secondary outcomes include 
defined daily doses of antibiotics (analysed weekly from 
randomisation to day 28), all- cause mortality (from day 
4 to day 30 following BCx extraction), readmissions in 
the next 90 days (from day 4 to day 90 following BCx 
extraction), rate of reinfection by multidrug- resistant 
bacteria (in the first 3 months after the negative BCx),13 
rate of patients presenting with confirmed Clostridium 
difficile- associated diarrhoea (in the first 3 months after 
the negative BCx). Secondary objectives are the eval-
uation of the impact of a specific ASP in patients with 
negative BCx aimed at: (1) reducing the use of broad- 
spectrum antibiotics, (2) reducing the incidence of Clos-
tridium difficile colitis.
An interim analysis is planned after 50% of the sample 
size has been included and monitored in order to ensure 
that there are no efficacy or safety reasons to prevent the 
trial from running to completion.
Evaluation of the results will be made in consensus by 
an independent committee blinded to the intervention 
assignment, made up of two experts from the Spanish 
Network for Research in Infectious Diseases (REIPI).
Sample size
Cohort study
Calculation of sample size was based on the proportion of 
positive and negative BCx. We estimate that at least 100 
episodes of positive BCx will be needed to compare the 
two populations. Since the proportion of positive/nega-
tive BCx in the participating hospitals is 1:10 on average, 
a sample size of 1000 was estimated. The average number 
of BCx taken in the participating hospitals is around 
8000 per year per hospital. It is expected that 50 BCx per 
month, per hospital will be included every month for six 
consecutive months in order to obtain the total of 1000 
BCx (120–160 positives).
Cluster-randomised trial
The following parameters were used for calculation 
of sample size: beta error (<80%), alpha error (<5%), 
mean duration of antibiotic treatment in the control 
group (10.8 days±4.56). The estimate was based on an 
analysis of patients with pneumonia and negative BCx 
in an intervention study conducted in 2016 at two of the 
participating hospitals. The acceptable margin of error 
between groups is ≤20%. Considering that 18 clusters will 
participate and taking into account a high intra- cluster 
interaction coefficient of 0.4, the estimated sample size is 
756 patients (378 to intervention or control). In order to 
anticipate loss to follow- up, a total of 800 patients should 
be included, 22 per period and participating cluster.
Statistical analysis
Cohort study
Descriptive statistics will be used to analyse demographic 
data. Univariate and multivariate analysis with binary 
logistic regression will be used to evaluate the variables 
associated with inadequate treatment. Logistic regression 
will be used to analyse differences in mortality rate up 
to 30 days. Subgroup analyses will be performed for the 
main outcome (percentage of inadequate treatment) and 
secondary outcomes (mortality, readmissions, length of 
stay and admission to ICU). Subgroups will be: critically 
ill patients, immunocompromised patients, neutropenic 
patients, depending on the main syndromes/specific 
foci, type of infection acquisition and whether or not the 
micro- organisms isolated were present in other biological 
samples.
Cluster-randomised trial
For the main outcome, absolute differences in means 
between the two arms of the intervention will be calcu-
lated with 95% CIs. Multivariate analysis using linear 
regression will be performed to ensure the indepen-
dence of the effect of the intervention on the main vari-
able (DoT). An analysis stratified by focus and severity of 
infection will be carried out at the time of BCx extraction.
An interim analysis will be performed when 50% of 
the population has been recruited. The interim analysis 
will be evaluated by a Data Monitoring and Safety Board 
made up of three independent infectious disease physi-
cians. The study will be stopped if a >15% difference 
in mortality is found. Nevertheless, any differences in 
mortality will be carefully assessed for potential causality.
The Desirability of Outcome Ranking (DOOR)/
Response Adjusted for Duration of Antibiotic Risk 
(RADAR) methodology will be applied to analyse the 
effect of the intervention.14 Analyses of data and feedback 
reports will be circulated to the study teams on a quarterly 
basis.
The following populations will be considered: the 
intention- to- treat population (includes all randomised 
patients; the per protocol population includes all 








pen: first published as 10.1136/bmjopen-2019-030062 on 18 December 2019. Downloaded from 
6 Jiménez- Jorge S, et al. BMJ Open 2019;9:e030062. doi:10.1136/bmjopen-2019-030062
Open access 
full intervention (visit 1 day 3 audit and visit 3 days 5–7 
audit).
A small proportion of patients is likely to go on to have 
a positive culture after the intervention on day 3. This 
population will be considered for subgroup analysis. The 
‘having a late positive culture’ variable will also be consid-
ered as a possible predictor of outcome (in both the effi-
cacy and the safety analyses).
legal and ethical considerations
The agreement of the directors of the institutions (who 
signed the clinical study agreement with the study 
sponsor) and the authorisation of the Spanish Regu-
latory Agency (Agencia Española del Medicamento y 
Productos Sanitarios) was also obtained. The study will be 
conducted in compliance with the protocol, regulatory 
requirements, the International Council of Harmoniza-
tion (ICH) E6 Good Clinical Practice guidelines, and the 
ethical principles of the latest version of the Declaration 
of Helsinki adopted by the World Medical Association. 
The relevant ethics committee(s) will be notified of each 
substantial protocol amendment for their approval prior 
to implementation. All data collected will be kept strictly 
confidential in accordance with all relevant legislation 
on the control and protection of personal information. 
Participants will be identified on documentation by a 
unique ID number, not by name. All study- related infor-
mation will be stored securely at the study sites.
Patient and public involvement
No patient involved.
dISCuSSIon
The aim of this study is to assess the impact of an antimi-
crobial stewardship intervention on patients with nega-
tive BCx. To do this, we designed a two- step study: an 
exploratory cohort of patients who have had BCx taken, 
followed by a cluster- randomised trial in which an ASP 
intervention will be implemented in a population of 
subjects with negative BCx.
It has been widely demonstrated that management 
and clinical outcomes in patients presenting bacteraemia 
improve when infectious diseases specialists partici-
pate.15 Furthermore, interventions on patients with sepsis 
have also been shown to be effective in terms of clinical 
results.16 However, no literature can be found focused 
specifically on ASP interventions in patients with nega-
tive BCx. These patients may represent different clinical 
scenarios. First, a patient with a negative blood culture 
may be an individual with no infectious syndrome, in 
which case antibiotic treatment would be unnecessary 
and should be avoided to prevent unintended conse-
quences such as toxicity or resistance selection. At the 
same time, a negative BCx can be found in patients with 
severe infection and serious clinical conditions, in which 
case, the previous antibiotic treatment may invalidate the 
blood culture results. The idea of an exploratory cohort 
therefore is to select the subgroup of susceptible patients 
with negative BCx where an ASP intervention may be 
more effective in terms of outcome.
The study methodology was selected in order to mini-
mise confusion and ensure its feasibility, given that it is an 
educational intervention in which it is possible to control 
contamination by prescribers. In an individual interven-
tion in which the assigned unit is the patient, situations 
may arise where the same prescriber treats patients in 
both the intervention group and the control group. If the 
intervention unit is the set of prescribing doctors, clini-
cians from the same department can interact with each 
other, thus affecting the impact of the intervention. A 
cluster- crossover design where all participating clusters 
(clinical units) receive both intervention and control 
assignment minimises these limitations, reduces the total 
number of clusters required and consequently, the study 
duration.17
The NO- BACT study has several strengths. It was 
designed with daily clinical practice in mind and with 
a robust design to control for potential confounding 
factors. The findings could make a notable contribu-
tion to achieving good control of severe infectious 
syndromes in patients not included in sepsis or bacter-
aemia programmes, in other words, patients without 
typical syndromes at presentation, such as neutropenia or 
elderly people in which optimised antimicrobial manage-
ment could help achieve better clinical outcomes.
There are several limitations in this study that should 
be taken into account. First is the risk of selection bias, 
or how the use of a cluster randomisation introduces 
bias through the way patients are differentially recruited 
across study groups. Although the most suitable candi-
dates for the intervention will be selected on the basis of 
the exploratory cohort, patients included in the partic-
ipating clinical units may present with different under-
lying characteristics. In this context, the crossover design 
may help partially control selection bias since the same 
cluster will participate in both the interventional and 
control groups.
Second, the nature of the ASP intervention may consist 
basically of an unsolicited advice programme by an ASP 
expert. Although a standard methodology will be imple-
mented, based on a predetermined system and with 
previous training given, the intervention is inherently 
subjective because the quality of antibiotic use will be 
assessed by an ASP physician. Hence, peer evaluation 
based on an antimicrobial reference guide has been 
implemented.
Since the intervention is not blinded, the main outcome 
could be affected. To minimise this, a robust primary 
outcome, ‘DoT’, was selected, and external assessment by 
a blinded committee added.
Third, the study is powered to determine whether 
there is a difference in duration of antibiotic use, but 
not powered to ascertain whether there is a difference in 
important clinical outcomes such as mortality, ICU admis-
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negative impact on clinical outcomes (such as mortality), 
a positive result will indicate that this approach can be 
used. Statistically, speaking, this can only be ensured with 
a primary outcome of clinical efficacy, and a secondary 
outcome of duration of antibiotics. In order to mitigate 
this commonly observed limitation of previous antimicro-
bial stewardship trials, a mortality threshold of ±15% will 
be allowed, in addition to the performance of multivar-
iate and subgroup analyses focused on safety outcomes.
Another major concern is associated with informed 
consent. The latest update of the European Union Regu-
lation (536/2014) on clinical trials in medicinal prod-
ucts for human use includes some of the issues involved 
in obtaining informed consent in cluster trials, in which 
groups of subjects rather than individuals are assigned to 
receive different interventions.11 18 In our study, a CRT 
involves a cluster- level public health intervention in which 
the health professionals in the participating clinical units 
are the subjects of this educational intervention. The 
study involves no more than minimal risk to the patients 
treated. Patients will be verbally informed of their partici-
pation in the study and treated according to good clinical 
practice. A waiver of informed consent for the study inter-
vention was granted by the institutional review boards 
involved and the Spanish Regulatory Agency.
In conclusion, the findings of our study could support 
implementation in clinical practice of an antimicrobial 
stewardship intervention to optimise use of antibiotics in 
patients in the selected population with negative BCx.
Trial status
The status of the trial at submission is 486 patients 
recruited in the cohort study (49% of the estimated 
recruitment per protocol); CRT will begin after the 
cohort study.
Current protocol approved is V.1.0 dated 26 February 
2018.
Date recruitment began: 8 October 2018 (Cohort); 
expected start for the CRT, October 2019.
Approximate date when recruitment will be completed: 
June 2019 (Cohort), June 2020 (CRT).
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